Paraguay
Tuberculosis profile
Population  2012 6.7 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.2 (0.16–0.24) 3 (2.5–3.6)
Mortality (HIV+TB only) 0.043 (0.035–0.05) 0.64 (0.53–0.75)
Prevalence  (includes HIV+TB) 4.2 (2.1–7.1) 63 (31–106)
Incidence  (includes HIV+TB) 3 (2.8–3.2) 45 (41–48)
Incidence (HIV+TB only) 0.24 (0.22–0.26) 3.5 (3.3–3.8)
Case detection, all forms (%) 81 (75–88)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 1 391 (61) Relapse 123 (37)
Smear-negative 221 (10) Treatment after failure 16 (5)
Smear-unknown / not done 273 (12) Treatment after default 53 (16)
Extrapulmonary 221 (10) Other 138 (42)
Other 187 (8)      
Total new 2 293   Total retreatment 330  
           
Other (history unknown) 0        
Total new and relapse 2 416   Total cases notified 2 623  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.3 1.5 1.9
Age < 15 20 191 25
Laboratories 2012
Smear (per 100 000 population) 1.8
Culture (per 5 million population) 8.2
Drug susceptibility testing (per 5 million population) 0.7
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 78   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 60  
Retreatment 67  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 906 (73)
HIV-positive TB patients 154 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 93 (60)
HIV-positive TB patients on antiretroviral therapy (ART) 121 (79)
HIV-positive people screened for TB 412  
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 0.31 (0.01–1.7) 15 (6.1–28)
MDR-TB cases among notified pulmonary
TB cases
7 (0–36) 48 (20–92)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 235 (15%) 89 (27%) 329
Laboratory-confirmed MDR-TB cases 1 6 7
Patients started on MDR-TB treatment     6
Financing TB control 2013
National TB programme budget (US$ millions) 4.3
% Funded domestically 37%
% Funded internationally 29%
% Unfunded 34%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data